Tisotumab Vedotin

CHEMBL4297841 Phase 4 Disetujui Antibody drug conjugate

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Tisotumab vedotin is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody targeting tissue factor (TF/CD142), conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxin. Upon binding to TF-expressing tumor cells, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis; TF-expressing tumor cells also receive direct antibody-mediated cytotoxicity. It is approved for recurrent or metastatic cervical cancer and is under investigation for bladder and non-small cell lung cancers.

Area Terapeutik

Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Tisotumab vedotin is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody targeting tissue factor (TF/CD142), conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxin. Upon binding to TF-expressing tumor cells, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis; TF-expressing tumor cells also receive direct antibody-mediated cytotoxicity. It is approved for recurrent or metastatic cervical cancer and is under investigation for bladder and non-small cell lung cancers.

Yes, Tisotumab Vedotin is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297841. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Tisotumab Vedotin di PillFYI

Data Cepat

Sinonim: 1

Tautan Eksternal

ChEMBL CHEMBL4297841

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.